Bradley D Stein1, Flora Sheng2, Erin A Taylor3, Andrew W Dick4, Mark Sorbero5, Rosalie Liccardo Pacula6. 1. RAND Corporation Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, USA. Electronic address: stein@rand.org. 2. RAND Corporation, Arlington, VA, USA. Electronic address: fsheng@rand.org. 3. RAND Corporation Santa Monica, CA, USA. Electronic address: etaylor1@rand.org. 4. RAND Corporation Boston, MA, USA. Electronic address: andrewd@rand.org. 5. RAND Corporation Pittsburgh, PA, USA. Electronic address: sorbero@rand.org. 6. Price School of Public Policy, University of Southern California, Los Angeles, CA, USA. Electronic address: rmp_302@healthpolicy.usc.edu.
Abstract
BACKGROUND: Multiple state policies, such as prescription drug monitoring programs (PDMPs) and duration limits, have been implemented to decrease high-risk opioid prescribing. Studies demonstrate that many policies decrease certain opioid prescribing behaviors, but few examine their intended effects on the targeted high-risk prescribing practices, nor disentangle the effects of concurrent state or federal policies likely to influence those practices. METHODS: Forty-one million initial prescriptions for new opioid episodes from 2007 to 2018 were identified using national pharmacy claims. We identified high-risk initial prescriptions, defined as >7 days' supply, average daily MME >90, or concurrent with benzodiazepines and estimated three multivariable logistic regression models to assess the association between policies and outcomes controlling for patient, prescriber, and county characteristics. RESULTS: Initial prescriptions for >7 days declined from 23.8% in 2007 to 14.9% in 2018, associated with mandatory and interoperable PDMPs and prescription duration limits but not other policies examined. Initial prescriptions with daily MME > 90 declined from 13.2% to 1.9%, associated with pain management clinic laws but not consistently with other policies. Initial prescriptions concurrent with benzodiazepines declined only modestly from 6.9% to 6.5%, associated with pain management clinic laws but not other policies examined. CONCLUSIONS: The opioid policy environment has changed rapidly with a range of different policies being implemented addressing high-risk prescribing. PDMP laws mandating prescriber use and pain clinic laws both appear efficacious but decrease different types of high-risk opioid prescribing. New policies should be considered in light of the prevalence of the problem being addressed.
BACKGROUND: Multiple state policies, such as prescription drug monitoring programs (PDMPs) and duration limits, have been implemented to decrease high-risk opioid prescribing. Studies demonstrate that many policies decrease certain opioid prescribing behaviors, but few examine their intended effects on the targeted high-risk prescribing practices, nor disentangle the effects of concurrent state or federal policies likely to influence those practices. METHODS: Forty-one million initial prescriptions for new opioid episodes from 2007 to 2018 were identified using national pharmacy claims. We identified high-risk initial prescriptions, defined as >7 days' supply, average daily MME >90, or concurrent with benzodiazepines and estimated three multivariable logistic regression models to assess the association between policies and outcomes controlling for patient, prescriber, and county characteristics. RESULTS: Initial prescriptions for >7 days declined from 23.8% in 2007 to 14.9% in 2018, associated with mandatory and interoperable PDMPs and prescription duration limits but not other policies examined. Initial prescriptions with daily MME > 90 declined from 13.2% to 1.9%, associated with pain management clinic laws but not consistently with other policies. Initial prescriptions concurrent with benzodiazepines declined only modestly from 6.9% to 6.5%, associated with pain management clinic laws but not other policies examined. CONCLUSIONS: The opioid policy environment has changed rapidly with a range of different policies being implemented addressing high-risk prescribing. PDMP laws mandating prescriber use and pain clinic laws both appear efficacious but decrease different types of high-risk opioid prescribing. New policies should be considered in light of the prevalence of the problem being addressed.
Authors: Lindsey E Dayer; Meghan N Breckling; Brittanie S Kling; Mrinmayee Lakkad; Elizabeth R McDade; Jacob T Painter Journal: J Emerg Med Date: 2019-10-05 Impact factor: 1.484
Authors: Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff Journal: Ann Intern Med Date: 2010-01-19 Impact factor: 25.391
Authors: Megan S Schuler; Sara E Heins; Rosanna Smart; Beth Ann Griffin; David Powell; Elizabeth A Stuart; Bryce Pardo; Sierra Smucker; Stephen W Patrick; Rosalie Liccardo Pacula; Bradley D Stein Journal: Drug Alcohol Depend Date: 2020-06-27 Impact factor: 4.492
Authors: Carroline P Lobo; Gerald Cochran; Chung-Chou H Chang; Walid F Gellad; Adam J Gordon; Hawre Jalal; Wei-Hsuan Lo-Ciganic; Jordan F Karp; David Kelley; Julie M Donohue Journal: Pain Med Date: 2020-09-01 Impact factor: 3.750
Authors: Emma E McGinty; Mark C Bicket; Nicholas J Seewald; Elizabeth A Stuart; G Caleb Alexander; Colleen L Barry; Alexander D McCourt; Lainie Rutkow Journal: Ann Intern Med Date: 2022-03-15 Impact factor: 51.598
Authors: G Thomas Ray; Andrea Altschuler; Ruchir Karmali; Ingrid Binswanger; Jason M Glanz; Christina L Clarke; Brian Ahmedani; Susan E Andrade; Joseph A Boscarino; Robin E Clark; Irina V Haller; Rulin Hechter; Douglas W Roblin; Katherine Sanchez; Bobbi Jo Yarborough; Steffani R Bailey; Dennis McCarty; Kari A Stephens; Carmen L Rosa; Andrea L Rubinstein; Cynthia I Campbell Journal: JAMIA Open Date: 2022-05-17
Authors: Julia Dickson-Gomez; Sarah Krechel; Antoinette Spector; Margaret Weeks; Jessica Ohlrich; H Danielle Green Montaque; Jianghong Li Journal: Subst Abuse Treat Prev Policy Date: 2022-07-21